September 28, 2020
Home Archive by category Health

Health

Health

The trial of the covid-19’s AstraZeneca Oxford vaccine was cancelled after a volunteer in Britain became ill. Now the trial is going to start again .

Dr. Dheeraj Kaul from New York said on call that Volunteer in the UK had to stop the trial of the AstraZeneca Oxford vaccine due to a problem with the nervous system. This problem has no relation with this vaccine.

Corona virus
Corona Virus

Kaul told that Serum Institute of India is going to produce this vaccine. Therefore, during the worldwide trial of this vaccine, it was important to inform the Drug Controller of India, if there is any effect on Volunteer anywhere.

Kaul appreciated the Government of India and said that the government provided all kinds of facilities. After this all company took an irresponsible stand. In the of this epidemic, private companies will have to act responsibly.

Significantly, DCGA issued a notice to SIE on September 9 for not providing information about AstraZeneca’s trial of vaccines in other countries.
He said that in russia , china and america in third stage they are allowing to apply vaccine on humans after 50-60 % successful trials.it is usually allowed to experiment directly on humans only after 95% of successful trials.

Kaul said that 9 vaccines are currently on the third stage of the human trial to control Covid-19. In such a situation, the responsibility of institutions to work on it increases. At the same time India has started the production of chemical, so that the relation of dependence on China should be reduced.
The Controller General of India, VG Somani, in an order on Friday, also asked the Serum Institute of India (SII) to increase the safety of those who has been vaccinated during the trial. Also present plans and reports.

With respect to the order, Somani has also asked the company to submit approval from the Data and Safety Monitoring Board (DSMB) in the UK and India for approval from their office (DCGA) before making new settings for future tests. .

A statement from the Oxford University stated that oxford corona vaccine’s trials will be resumed at all UK testing centers. Although its time has not been mentioned.

According to the statement, around 18,000 people globally received the study vaccines. In these large trials it is assumed that some participants will become not well . At the end their safety should be carefully managed or evaluated.

On the other hand, Professor Fiona Watt( president of the UK’s Medical Research Council), said that safety is importance in developing any new drug. It is therefore reassuring that the Oxford Corona Virus vaccine trial will resume after review by an independent safety committee and MHRA.
Professor Sian Griffiths at the Chinese University of Hong Kong said that it is good news that the Oxford vaccine trial is starting again.

The process of stopping the test high value and importance to ensure vaccine safety, despite the pressure of vaccine production. It is expected that data is studied by the authorities.

Deepak sen
Senior journalist

Health

New Delhi: According to the latest development from USA, USA is ready for vaccine of Covid-19 in all its states in early October. Just a few weeks ago, Russia announced the Covid-19 vaccine.

According to US-based sources, the three major companies in the US are ‘Moderna’, ‘BioNTech and Pfizer’ and ‘AstraZeneca Oxford’. Covid — 19 vaccines of these three companies — is on the third stage of the ‘human trial’ vaccine.

Sources said that the US government has decided that in view of the encouraging results of the ‘Human Trial’ on the third stage, these vaccines should be applied directly to the citizens. For this, the vaccine of Covid-19 being prepared by the companies should be distributed in the States of America.

As per reports, the Serum Institute of India will begin human trials for the AstraZeneca Oxford Vaccine from August.

“At present, we are working on the AstraZeneca Oxford vaccine which is undergoing phase III clinical trials. In addition to this, we will also start human trials in India in August 2020. Based on the current situation and most recent updates on the clinical trials, we are hoping that the AstraZeneca Oxford vaccine will be available towards the end of this year,” Serum Institute of India CEO Adar Poonawalla told a news agency.

According to sources, it is highly likely that the vaccine being prepared by ‘Moderna’ and ‘BioNTech and Pfizer’ among the three can be used on citizens. The vaccines of these two companies require very low temperatures to be kept. Therefore, the group ‘CPC’, which is overseeing the Corona cases in the US, has asked all the states of the country to be vigilant.

Significantly, Covid — 19 in the US — has infected the most people and killed the most.

According to sources, there is a lot of pressure on the Trump government in the United States in view of the upcoming presidential elections. Perhaps this is the biggest reason that the US government has decided to bring out the vaccine as soon as possible which has reached the third stage on the lines of Russia to the citizens of our country.

The thing to be seen here will be how long and how much the US gives the vaccine to India. India lifted the ban on hydroxychloroquine in early May to help the US combat the Corona virus.

Significantly, Prime Minister Narendra Modi had pledged to use the full power of the Indo-US partnership in the fight against US President Donald Trump.

Deepak sen
Senior journalist

Health

In the wake of COVID-19, Pharma marketing is embracing digitisation. India’s share in world’s Vaccine production is 50%, making it the largest supplier

21st August 2020: Hardly any industry has left unaffected due to the unprecedented scourge of COVID-19. And the pharma industry is no exception to this. What sort of challenges Pharma industry has gone through during COVID-19 times? How digital adoption has been helpful and successful? How the new decade of pharma industry post COVID-19 will play out? And what will be the challenges of Pharma MSME and its solutions. These were some of the important topics discussed at length in the Emerging dimensions of Pharma Excellent eSummit held on 20th August 2020 organised by HEAL Health Connect Solutions in association with HealthScape.

Corona virus
Corona Virus

The magnitude of COVID-19 is unprecedented in the modern world. And currently, only supportive care is available wherein repurposing of drugs is the most feasible approach to tackle the situation. Drug repurposing is nothing but using an approved drug for the treatment of a disease or medical condition other than what it is approved for. In COVID-19 scenario, this method is very useful in addressing the disease quickly since these drugs are approved, readily available off the shelf, their safety for human use is established and their side effect profile is well known. The technology of drug repurposing has the capability of breathing a new lease of life in the healthcare and pharma sector of India.

Speaking about the challenges that Pharma industry has faced during the lockdown and its move towards digital adoption in the Pharma Excellence eSummit-2020, Mr Sudarshan Jain, Secretary General of Indian Pharmaceutical Alliance (IPA), said, “COVID-19 has posed the greatest humanitarian challenge, however, in such a time of crisis, healthcare and pharma industry have played an important role. And more significantly, India has been at the forefront in repurposing the drugs as it has a large share in supplying drugs to the world. The role of India has been immense in maintaining the supply chain to the world. Now, Indian pharma industry has been gearing up not only for ‘Make in India’ but also for ‘Make for the world’.

“Also, during COVID-19, we see the following things happening in the Indian pharma industry.

  1. Repurposing of the drugs
  2. Increase in the production of vaccines as it contributes to 50% of the total production of the world.
  3. The development of Standard Operating Procedure (SOPs) in Indian pharma industry.
  4. Digital adoption in pharma industry.
  5. Adoption of Active Pharmaceutical Ingredient (API) in India
  6. Development of Human Resource
    Indian Pharma industry has been already exporting drugs to 206 countries, and it will grow more, showing the new path to the world not only in manufacturing drugs but also in Research & Development”, added Mr Jain.

Elaborating on the challenges of the pharma industry in COVID-19 times and the immediate solution which could help tackle the griming situation in the Pharma Excellence eSummit-2020, Mr O P Singh, President Sales & Marketing, Cadila Pharma, said, “Repurposing of drugs may be an immediate solution to combat the pandemic and saving the lives of the people, and it has been also tried out by the Indian pharma industry. For example, Sepsis has been repurposed for the treatment of COVID-19 and found to be efficacious. Now, Indian pharma industry has been heading towards innovation.”

Throwing light on the digital adoption and its significance in pharma marketing in the Pharma Excellence eSummit-2020, Mr Vivek Srivastava, Co-founder & CEO, HealthCare at Home, said, “I have seen large scale digital adoption across the country during COVID-19. Even in home isolation care, we have used digital platforms for consultations with the doctors. By the use of digital technology, we have treated almost 2500 odd patients in home isolation. Digital adoption is booming everywhere including pharma marketing.”

Speaking on the significance of digital education required for the doctors, Dr G S Grewal, President Elect, DMA, said, “This is the grave reality that in Delhi, even 30% of doctors didn’t have desktops in pre-COVID times. So, along with digital adoption, its proper education and training is essentially required.”

Overviewing the pre and post COVID Indian pharma industry perspective, Dr Swadeep Srivastava, Founder & CEO, HEAL Health Connect Solutions asserted, “Although there has been slump in pharma industry in Apr-Jun quarter, yet from July, the Indian Pharma industry is bouncing back on track, and likely to grow 3%-5% in size during FY 2020-2021 as per India Ratings and Research. In June, the demand for cardiac drugs registered the strongest growth of 15.9 per cent y-o-y in terms of value and anti-diabetic segment grew at 12.7 per cent y-o-y due to continued buying during the period of the lockdown.

Commenting on the accessibility of drugs in India Mr Atul Sharma, Founder & Managing Director, HealthScape said, “In Indian pharma industry, manufacturing volumes after declining to 50%-60% in April 2020, given the strict lock-down, has improved significantly to 60%-80% of the original capacities during May-June 2020. In India, we have been in a reasonably good position in terms of the accessibility of the drugs as it is easily available over the counter compared to the eastern European countries.”

About HEAL HEALTH CONNECT SOLUTIONS: Healthcare Communication par excellence is the prima facie impression of HEAL Health Connect Solutions. Its understanding of the healthcare ecosystem makes it stand apart when it comes to execution with precision. It devises the strategy based on demographics and psychographics of the potential audience and accordingly use their preferred channels of communication.

It has expertise of working across the healthcare delivery value chain – be it product or service. During COVID-19 times, it has been proactive with other healthcare stakeholders in inculcating awareness amongst the masses about the pandemic. To know more, visit: https://hhconnect.in/.

Health

Mumbai: A 60-year-old man Mr. Pankaj Shah (Name changed) from Chembur ignored his diabetes and ended up with uncontrolled diabetes and lower left leg gangrene. The patient underwent multiple debridements with the cleaning of wound with continuous irrigation negative pressure therapy (a special type of dressing) And his leg was saved at Zen Multispeciality Hospital, Chembur. He is scheduled to undergo skin coverage of the affected leg. He’s better and happy now.

Corona virus
Corona Virus

Life was smooth until the Mr. Pankaj Shah from Chembur got diabetes for more than 15 Years though sugars were well controlled and were under treatment. During the COVID-19 outbreak, he had a small leg injury which he ignored as he was worried to come out of the house due to fear of COVID. Later about one month after an injury he went to one of the local hospitals where he was advised for amputation (cutting leg to avoid further spread above the knee). The family didn’t agree and was wheeled into emergency at the Zen Multispeciality Hospital, Chembur, Mumbai. The patient was admitted on 7th July 2020 and surgery was performed on 13th July 2020.

Dr. Roy Patankar, Director, Zen Multispeciality Hospital, Chembur highlighted, “There are many cases wherein people ignore their health problems due to the fear of contracting COVID infection and land themselves in grave situations that can be even life-threatening. Owing to the pandemic, people are scared to visit the doctor, resort to self-medication, and come in an emergency due to the delay in treatment. Some may also require complex surgeries but this is entirely avoidable if one takes a prompt treatment.”

This patient too neglected his uncontrolled blood sugar levels and came with left lower leg gangrene. It occurs when blood flow to a certain area of your body is interrupted, leading to tissue decay and death. The chances of developing gangrene are higher if one has an underlying condition that can damage the blood vessels and affect blood flow, such as diabetes or hardened arteries (atherosclerosis). The patient was scheduled to undergo treatment for gangrene include surgery to remove dead tissue and salvaged his leg. He is underdressing now and will require another surgery to cover the open wound (skin grafting).”

Dr. Patankar adds, “Video consultation during these unprecedented times can be a good option but in various survival situation it is very important to visit the hospital. It can prevent one’s condition from worsening as it can update the doctor about the person’s health, and will help to determine how serious the condition is. Don’t refrain from visiting the hospital as the COVID-19 protocol is followed. The hospitals are taken measures such as practicing social distancing, wearing PPEs and masks, disinfecting surfaces and equipment, checking temperature, and limiting the number of visitors. Avoid ignoring Non-COVID illnesses and opt for timely treatment that can save your life.”

Mr. Pankaj Shah, the patient says, “Due to the fear of COVID I was avoiding to go to Hospital for the leg injury treatment. Being a diabetic patient, we have to take care of our wound but due to fear of COVID cases, I had delayed in treatment which led to cutting leg to avoid further spread above the knee. I am grateful to Dr for giving me timely treatment and save my leg. I am happy and will soon go for further treatment.”

Health

Changing dynamics in healthcare sees new adaptations such as change in Doctor-Patient relationship and availability of time for doctors to rediscover themselves

The unfolding situations of COVID-19 in India exemplify that it is here to stay. No one expected that the pandemic will change the dynamics of healthcare, setting a new normal. As the pandemic is all set to change healthcare, we need to know certain things. Where do we stand in the pandemic? Are Vaccines or medicines still a distant dream?

The future of the healthcare industry in India in post COVID. To discuss these important issues, the largest 2nd India Healthcare e-SUMMIT was organised on 6th August 2020 by HEAL Foundation — a healthcare advocacy group in association with ICCIDD wherein experts from across the spectrum participated and deliberated on respective significant issues.

Throwing light on the future of the healthcare industry post COVID during the 2nd India Healthcare e-SUMMIT, Mr Anand Shrivastava, Chairman, Maharishi Ayurveda, said, “COVID-19 has taught us so many lessons in healthcare such as how to continue our lives in the emerging new normal as it is going to stay with us. Especially, it has taught us that we can’t live with comorbid conditions now. We need to make our immunity stronger.”

In the changing dynamics of healthcare practises and emerging new normal, opinions from across the sectors about the essence of ‘Home Care’ which seems to be the affordable and accessible solution in such a time of crisis have been gaining ground.

Elaborating on the essence of ‘Home Care’ during the 2nd India Healthcare e-SUMMIT, Mr Vivek Srivastava, Co-Founder & CEO, HealthCare atHome, said, “There has been a dramatic change in the acceptance of Home Care in the wake of the outbreak of COVID-19. A large number of people are opting for Home Care and we have been receiving an increased number of queries. Even in a survey with an oncologist, it came out that 50% of cancer patients are seeking chemotherapy at home.

There has been a dramatic shift at all levels whether patients, doctors or government. The Delhi Government has also recommended for Home Care at massive scale. And insurance companies are also covering all aspects of our services in-home care. We are the first to launch Home Isolation services in the country, and we are running it for all Fortis Hospitals across the country and for Delhi government as well.”

Answering a query regarding doctor-patient relationship during the 2nd India Healthcare e-SUMMIT, Dr Sonia Lal Gupta, MD Metro Group of Hospital, said, “The importance of Doctor-patient relationship in terms of understanding the disease and the adherence of the therapy has increased in COVID times. Education and awareness is the only way to curb the upsurge of the pandemic. The COVID-19 has brought one big thing in healthcare — Telemedicine. India can develop Public Private Partnership (PPP) for better accessibility and affordability of healthcare for everyone.”

On the prevalent changes brought about in the lives of Doctors by COVID-19, Dr Sushil Kumar Jain, Laparoscopic Surgeon, Apollo Hospital, New Delhi, said during the 2nd India Healthcare e-SUMMIT, “As the doctors are the busiest lot always fall short of time, and earlier they couldn’t manage quality time for their families as well as following their hobbies and other necessary pursuits, but during COVID-19, they are able to spare time for themselves. Now they manage time to connect with their kith and kin, though digitally.”

“We need to learn how to live with the emerging new normal. Don’t fear, think positive and be positive. In the tough times of COVID, there has been lots of medical supply. We are running 400 home offices to facilitate the supply chain. We are also using drone services to improve the possible supply of essential medical devices and consumables in remote and hilly areas”, said, Mr Vivek Tiwari, Founder & CEO, Medikabazaar.
Speaking on how to take care of the mental health of children, Ms Yvonne Biggins, Mental Health & Wellbeing Expert, Day to Day Health, London, UK, said, “It is very important to provide safety and assurance to children, deal them with gratitude and kindness during the pandemic.”

Speaking in the 2nd India Healthcare e-SUMMIT, Ms Shwetima Jamwal, RJ, 98.3, Radio Mirchi, J&K said, “Every tough time makes us learn new things, and during the ongoing unprecedented COVID-19 pandemic, we have been learning new things day by day such as how to face the difficulties and overcome challenges. We are getting stronger in testing time.”

About HEAL Foundation: HEAL Foundation is a not-for-profit organisation and a ‘healthcare advocacy’ group which has been working diligently under its flagship initiative COVIDFighters — dedicated to fighting COVID-19 Pandemic with its various awareness drive such as organising a series of webinars and other allied activities ever since the outbreak of coronavirus. To know more about HEAL Foundation, visit: www.healfoundation.in and about its dedicated program on COVID-19 @ www.covidfighters.in.

About ICCIDD: Association for Indian Coalition for Control of Iodine Deficiency Disorders (ICCIDD) was established in 1997 to conduct research on the problems of Iodine deficiency disorders and other Micronutrients, Nutrition & Healthcare Delivery, Environment and Development in the community and suggest solutions.

Health

Mumbai, August 04, 2020: Sun Pharmaceutical Industries Limited. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that it has launched FluGuard® (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

Commenting on the launch, Kirti Ganorkar, CEO of India Business, Sun Pharma said, “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response.”

The company will work closely with the government and medical community to ensure availability of FluGuard® to patients across the country. The stocks of FluGuard® will be available in the market from this week.

FluGuard® is the registered trade mark of Sun Pharma.

Health

It has been a successful 9 days of mass testing and collection of thousands of samples from India for the trials of new technologies for rapid, non-invasive COVID-19 testing. The trials are a part of a crucial collaboration between DRDD, Ministry of Defence Israel and DRDO, PSA of India; coordinated by Ministry of Foreign Affairs Israel and India. The data collected from India will be corroborated with samples collected from Israel to find an effective diagnostic solution and help both countries in tackling the ongoing pandemic. If all goes according to plan, the rapid tests are expected to be available for mass use within a few months.

Ambassador of Israel to India, H.E Ron Malka and Mr. Amitabh Kant, CEO Niti Ayog visited the special testing site created at the Dr Ram Manohar Lohia (RML) Hospital today to witness the ongoing trials.

Speaking on the occasion, Mr Amitabh Kant, CEO Niti Aayog said, “I am pleased and proud to see the great advances made by Indian and Israeli scientists working together on Covid-19 Research and Development. If their cooperation produces the expected results, this will be a path breaking development for the entire world. I see immense potential here for continuing scientific and technological cooperation, and India will provide all the necessary expertise, personnel and resources needed for this and future missions.”

Speaking on the collaboration, H.E. Ron Malka, Ambassador from Israel in India said, “We had offers from other countries for this collaboration but decided to go with India because we have excellent relations with the country and there have been many successful collaborations between the India and Israel in the past. Not only are we confident about the scientific and technological capabilities of India, but once the R&D stage is over, we are also looking to collaborate with India for manufacturing as they have excellent industrial infrastructure for large scale production.”

The trials began on 28th July and are being conducted under the guidance of the Israeli delegation at 6 locations in Delhi – Dr Ram Manohar Lohia Hospital, Lok Nayak Hospital, Sir Ganga Ram Hospital, the DRDO office in Rohini, Akash Hospital and Lady Hardinge Hospital. The data collected in Delhi, along with the samples previously collected in Israel, will assist in developing and validating the algorithm of the AI technologies used in the tests. Such technologies will not just be restricted to the Coronavirus, but also have the potential to overcome any biological threat or pandemic of such scale in the future.

Speaking on the functionality and importance of the tests, Cdr. Yaniv Meirman, DDR&D Attache from Israel, says, “Unlike other existing Covid tests, these rapid tests have the potential to open up the economies fully and make international travel and day-to-day activities possible again. A person can just take these simple, affordable tests at home and check whether he will be able to go to work or go to public places without the risk of transmission. This will be a game-changer in terms of quickly diagnosing the virus by the people themselves.”

Four different technologies are being developed for quick detection of coronavirus, and the success of even one of them of them could provide a breakthrough, globally. The first is a breath analyser that requires a person to blow through a tube, after which a high frequency scan is used to analyse the humidity in the breathe and detect the presence of the virus in less than a minute. The second test is a thermal test which requires a saliva swab and has the potential to be purchased off the shelves and used at home itself, similar to an at-home pregnancy test. The third technology uses polyamino acids which can detect the proteins present in the virus in 45 seconds. Lastly, an audio recording test is also being developed that can be downloaded and used as a mobile phone application. The test will detect the changes in a person’s voice to detect COVID-19 and other lung diseases. Once the technologies are validated, the aim is to make the tests accessible to the masses at low rates and achieve higher accuracy rates than the current PCR test.

Cdr. Yaniv Meirman further added, “It has been an excellent experience working with the DRDO. We have also been impressed by the response of the hospitals and more importantly, the general Indian public who have come forward to volunteer and put in ample time and efforts to assist in this fight against corona virus. We are confident that by coming together, India and Israel will be able to achieve targets much faster and more efficiently than they would have managed on their own.”

These trials are a part of a multi-pronged mission visiting India from Israel to cooperate on COVID-19 research and development, further cementing the strategic relationship between the two nations.

Health

Juvenile arthritis
Yes! Children can also suffer from joint problems

New dimension for treating childhood arthritis-Exosomes

New delhi. Children sometimes complain about aches in their joints. A joint is where the ends of bones meet, such as the knee joint, shoulder joint, or the small joints in the fingers and toes. Joint pain in children can be caused by a variety of things.
An umbrella term for a group of chronic childhood arthritides of unknown cause, in children below sixteen years of age, and persisting for at least six weeks
Juvenile arthritis (JA) is an autoimmune disease, which means the immune system of the body attacks the cells of the joints and causes swelling and cartilage/bone damage. The condition is not a single entity but an umbrella of inflammatory and rheumatic diseases, and in instances the cause is unknown (idiopathic JA).

Dr. Pradeep V. Mahajan, Regenerative Medicine Researcher, Mumbai share Diagnosis and treatment on it .

Health

Our new normal comes with a new twist- face masks. An essential commodity which has now become a staple accessory in the fashion universe. Curated with extreme precautions in a safe and sterile environment, Samshék is happy to announce the launch of capsule collection-Iconic face masks offering a variety of designs that are affordable, re-usable, and in-vogue. It comes with three-layered protection, comfortable ear loops and suitable for both male and female. The starting price range for the collection is Rs 150/- each.

Now more than ever, supporting each other in this time of need has become their mission, which is why they will be donating 5% of their earnings to the ones in need.

Available at Amazon